Noriyuki Maeda Selected Research

alanyl-prolyl-arginyl-prolyl-glycine

1/2016	Enhanced Efficacy of Doxorubicin by microRNA-499-Mediated Improvement of Tumor Blood Flow.
5/2014	Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499.
3/2011	Dicetyl phosphate-tetraethylenepentamine-based liposomes for systemic siRNA delivery.
1/2011	Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector.
11/2008	Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
9/2006	Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs.
11/2004	Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
2/2004	Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Noriyuki Maeda Research Topics

Disease

17	Neoplasms (Cancer) 01/2022 - 02/2004
4	Carcinoma (Carcinomatosis) 03/2011 - 11/2004
2	Melanoma (Melanoma, Malignant) 01/2015 - 03/2011
2	Sarcoma (Soft Tissue Sarcoma) 05/2005 - 03/2004
1	Ascites 01/2022
1	Hemolysis 07/2020
1	Fibrosarcoma 03/2011

Drug/Important Bio-Agent (IBA)

13	Liposomes (Liposome)IBA 01/2022 - 02/2004
9	Peptides (Polypeptides)IBA 01/2016 - 02/2004
8	alanyl-prolyl-arginyl-prolyl-glycineIBA 01/2016 - 02/2004
5	Small Interfering RNA (siRNA)IBA 01/2022 - 01/2011
5	Triethylenephosphoramide (TEPA)IBA 01/2016 - 01/2011
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016 - 11/2004
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 11/2004
4	Pharmaceutical PreparationsIBA 01/2013 - 03/2004
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2010
2	LuciferasesIBA 01/2022 - 03/2011
2	TOR Serine-Threonine KinasesIBA 01/2015 - 01/2011
2	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 05/2014 - 03/2004
2	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2013 - 01/2011
2	Drug CarriersIBA 09/2006 - 11/2004
2	Verteporfin (Visudyne)FDA Link 05/2005 - 03/2004
2	1-phenyl-3,3-dimethyltriazene (PDT)IBA 05/2005 - 03/2004
2	1,2-distearoylphosphatidylethanolamine (DSPE)IBA 11/2004 - 02/2004
1	CytokinesIBA 01/2022
1	AlbuminsIBA 01/2022
1	ClathrinIBA 07/2020
1	Biological ProductsIBA 07/2020
1	tetraethylenepentamineIBA 01/2016
1	Sirolimus (Rapamycin)FDA Link 01/2015
1	Therapeutic UsesIBA 05/2014
1	LigandsIBA 01/2013
1	glycyl-arginyl-glycyl-aspartyl-serineIBA 01/2013
1	CholesterolIBA 03/2011
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2011
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2011
1	Endoplasmic Reticulum Chaperone BiPIBA 12/2010
1	Semaxinib (SU5416)IBA 11/2008
1	dpp-cndacIBA 05/2008
1	Photosensitizing Agents (Photosensitizers)IBA 05/2005
1	polyethylene glycol- distearoylphosphatidylethanolamineIBA 02/2004

Therapy/Procedure

8	Therapeutics 01/2016 - 02/2004
3	Drug Therapy (Chemotherapy) 01/2022 - 05/2008
2	Intravenous Injections 01/2015 - 05/2014
2	Lasers (Laser) 05/2008 - 05/2005
1	Photochemotherapy (Photodynamic Therapy) 03/2004